1. Home
  2. ALT vs ENGN Comparison

ALT vs ENGN Comparison

Compare ALT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ENGN
  • Stock Information
  • Founded
  • ALT 1997
  • ENGN 1999
  • Country
  • ALT United States
  • ENGN Canada
  • Employees
  • ALT N/A
  • ENGN N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ENGN
  • Sector
  • ALT Health Care
  • ENGN
  • Exchange
  • ALT Nasdaq
  • ENGN Nasdaq
  • Market Cap
  • ALT 327.4M
  • ENGN 321.5M
  • IPO Year
  • ALT N/A
  • ENGN N/A
  • Fundamental
  • Price
  • ALT $3.59
  • ENGN $6.16
  • Analyst Decision
  • ALT Strong Buy
  • ENGN Buy
  • Analyst Count
  • ALT 6
  • ENGN 8
  • Target Price
  • ALT $17.40
  • ENGN $21.50
  • AVG Volume (30 Days)
  • ALT 2.4M
  • ENGN 222.4K
  • Earning Date
  • ALT 11-11-2025
  • ENGN 09-11-2025
  • Dividend Yield
  • ALT N/A
  • ENGN N/A
  • EPS Growth
  • ALT N/A
  • ENGN N/A
  • EPS
  • ALT N/A
  • ENGN N/A
  • Revenue
  • ALT $20,000.00
  • ENGN N/A
  • Revenue This Year
  • ALT N/A
  • ENGN N/A
  • Revenue Next Year
  • ALT $761,880.20
  • ENGN N/A
  • P/E Ratio
  • ALT N/A
  • ENGN N/A
  • Revenue Growth
  • ALT N/A
  • ENGN N/A
  • 52 Week Low
  • ALT $2.90
  • ENGN $2.65
  • 52 Week High
  • ALT $11.16
  • ENGN $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ALT 45.32
  • ENGN 57.89
  • Support Level
  • ALT $3.54
  • ENGN $4.24
  • Resistance Level
  • ALT $3.72
  • ENGN $6.54
  • Average True Range (ATR)
  • ALT 0.16
  • ENGN 0.46
  • MACD
  • ALT 0.02
  • ENGN -0.23
  • Stochastic Oscillator
  • ALT 21.87
  • ENGN 94.19

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: